SavedAdd your journal

Journals / GORM:Gynecology Obstetrics & Reproductive Medicine / 2004 / Cilt: 10 - Sayı: 3

Do tibolone and combined hormone replacement therapy have a beneficial effect on plasma lipid levels in hyper and normocholesterolemic postmenopausal women?

Sürmen Sibel USTA
Taylan KUTLU
Sadiye EREN
Pages
186–190
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies with long-term follow-up including the outcomes of hypercholesterolemic women will help to explain the exact effects of this treatment option.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To compare the effect of tibolone and combined hormone replacement therapy (HRT) on plasma lipids in normo-and hypercholesterolemic postmenopausal women during a year period.
📊
Key Findings & Data:Study Design: A total of 150 postmenopausal women were enrolled in this prospective randomized study.
💡
Conclusion & Impact:Further studies with long-term follow-up including the outcomes of hypercholesterolemic women will help to explain the exact effects of this treatment option.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hormon replasman tedavisi · Androjen antagonistleri · Medroksiprogesteron

Abstract

Objectives: To compare the effect of tibolone and combined hormone replacement therapy (HRT) on plasma lipids in normo-and hypercholesterolemic postmenopausal women during a year period. Study Design: A total of 150 postmenopausal women were enrolled in this prospective randomized study. The women were first randomized into two groups receiving tibolone 2.5mg and conjugated equine estrogens (CEE) 0.625mg+continuous medroxyprogesterone acetate (MPA) 2.5 mg respectively. Then each group was divided into two subgroups according to their baseline LDL and total cholesterol concentrations. Fasting blood samples were monitored at baseline and after 12 months. Results: Tibolone did not significantly reduce the LDL cholesterol and triglyceride concentration either in normocholesterolemic or in hypercholesterolemic women. On the other hand, CEE+MPA significantly reduced LDL and total cholesterol levels in hypercholesterolemic postmenopausal women. Conclusion: This study represents the beneficial impact of CEE+MPA therapy on serum lipid levels of hypercholesterolemic women. However, Tibolone did not lower LDL and total cholesterol levels similar to CEE+MPA therapy. Further studies with long-term follow-up including the outcomes of hypercholesterolemic women will help to explain the exact effects of this treatment option.

🔖

Cite This Article

USTA, S. S., KUTLU, T., EREN, S. (2004). Do tibolone and combined hormone replacement therapy have a beneficial effect on plasma lipid levels in hyper and normocholesterolemic postmenopausal women?. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 10 - Sayı: 3, 186–190. https://ajindex.com/articles/227173

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Walsh BW, Schiff I, Rosner B, Greeberg L, Ravnikar V, Sacks F. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med, 1991; 325:1196-204
  2. Lobo RA. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects: Lipids and lipoproteins and effects of hormone replacement, Philedelphia: Lippincott Williams&Wilkins 1999:369-76
  3. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation., 2001; 104:1773-8 4. Williams DB, Voigt BJ, Fu YS, Schoenfeld MJ, Judd, HL. Assesment of less than monthly progestin therapy in postmenopausal women given estrogen replacement. Obstet Gynecol., 1994; 84:787-93
  4. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E. For the menopause study group. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol, 1994; 84:987-95
  5. Cagnacci A, Mallus E, Tuveri F, Cirillo R, Setteneri AM, Melis GB. Effect of tibolone on glucose and lipid metabolism in postmenopausal women. J Clin Endocrinol Metab, 1997; 82:251-3
  6. Al-Azzawi F, Wahab M, Habiba M, Akkad A, Mason T. Continuous combined hormone replacement therapy compared with tibolone. Obstet Gynecol, 1999; 93:258-64
  7. Hill AP, Dworsky R, Krauss, M. Hormone replacement therapy, hormone levels, and lipoprotein cholesterol concentrations in elderly women. Am J Obstet Gynecol, 1996; 174:897-902
  8. De Beer F, Smelt AHM, Van Vark LC, Hoogerbrugge N, Havekes LM, Gevers Leuven JA. The effect of tibolone on the lipoprotein profile of postmenopausal women with type 3 hyperlipoproteinemia. Journal of Internal Medicine, 2002; 251:148-55
  9. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril, 2001; 75:898-915
  10. Sanada M, Nakagawa H, Kodama I, Sakasita T, Ohama K. Three-year study of estrogen alone versus combined with progestin in postmenopausal women with or without hypercholesterolemia. Metabolism, 2000; 49:784-9
  11. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med, 1997; 337:595-601
  12. The Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expe